A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection

NCT05297565 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Nivolumab/rHuPH20
BIOLOGICAL: Nivolumab

Sponsor

Bristol-Myers Squibb